Key result
Campylobacter jejuni remains an essential chest pain differential to guide therapy when CMR is unavailable.
Case Report (n=1)
Highlights the importance of expanding the differential diagnosis for chest pain to include atypical pathogens like Campylobacter jejuni after excluding acute coronary syndrome.
Answers are grounded in this paper and cite their sources.
Reinforces detailed history-taking for targeted perimyocarditis therapy without CMR; extends known causes to Campylobacter jejuni.
BACKGROUND: Perimyocarditis is characterized by concurrent inflammation of the myocardium and pericardial sac. Multiple atypical etiologies may induce perimyocarditis. CASE SUMMARY: A 53-year-old man presented with pleuritic chest pain and 2 days of preceding watery diarrhea. Work-up revealed elevated troponins and elevated inflammatory markers, ST-segment elevations on electrocardiogram, and a nonobstructive coronary angiogram. Echocardiogram showed reduced left ventricular ejection fraction. Stool cultures positive for Campylobacter jejuni supported a diagnosis of C jejuni-associated perimyocarditis. Treatment included colchicine, guideline-directed medical therapy for heart failure, and levofloxacin. DISCUSSION: This case provides insights into the diagnostic and therapeutic challenges and a process for diagnosing perimyocarditis due to an atypical pathogen, such as C jejuni. TAKE-HOME MESSAGES: After excluding acute coronary syndrome, history taking and expanding the differential diagnosis of chest pain helps uncover etiology and targeted therapy. When cardiac magnetic resonance is unavailable, clinicians must use other modalities to support diagnosis and guide management.
No takes yet. Share an insight, caveat, or question.
Alexander et al. (2026) conducted a case report in Campylobacter jejuni-associated perimyocarditis (n=1). Campylobacter jejuni infection was evaluated. A 53-year-old man presenting with chest pain and watery diarrhea was diagnosed with Campylobacter jejuni-associated perimyocarditis and treated with colchicine, heart failure therapy, and levofloxacin.
Synapse has enriched 10 related papers. Consider them for comparative context: